English Ukrainian
Огляди літератури

QUINTIP RECORDATI INITIAL DATA CONCERNING THE PECULIARITIES OF HUMAN PAPILLOMAVIRUS INFECTION EPIDEMIOLOGY IN UKRAINE AND THE PROSPECTS FOR ITS PREVENTION

Published 2025-08-28

Authors:

A.I. Rybin
V.V. Osyk
R.S. Vastyanov
S.V. Liskovskyi
V.V. Artyomenko
Abstract:
The purpose of the study was to evaluate the human papillomavirus infection prevalence among women in different regions of Ukraine using the Quintip Recordati database. The Quintip Recordati database data, containing 195 records, was analyzed using frequency analysis methods. The distribution features of different HPV strains among the surveyed women living in other regions were determined. The frequency of seropositive results was analyzed also depending on the degree of urbanization. It was found that the number of positive tests was 38.5 % of the total sample size. When comparing the frequency of detection of highly oncogenic strains, it was found that they are more often registered in cities with a larger population. The authors showed that the prevalence of human papillomavirus infection in the surveyed women is twice higher comparing the average European level. Papillomavirus infection high prevalence in Ukraine is supposed to be the result of low vaccination coverage, lack of mass screening, lack of awareness and limited access to preventive programs. The frequency of detection of highly oncogenic HPV strains is higher in urbanized regions. The authors conclude that human papillomavirus infection diagnostic screening methods widespread implementation in Ukraine can significantly reduce the incidence of cervical cancer. They are sure that cervical cancer prevention will continue to rely on secondary prevention methods.
Keywords:
human papillomavirus epidemiology women's health screening prevention vaccination
References:
  1. Bondar OV, Rybin AI, Muzyka VV. Dosvid pervynnoho VPL-testuvannya u skryninhu raku shyyky matky Odeskyy medychnyy zhurnal. 2022; 1-2: 93-96. doi: 10.54229/2226-2008-2022-1-2-16 [in Ukrainian].
  2. Akhatova A, Azizan A, Atageldiyeva K, Ashimkhanova A, Marat A, Iztleuov Y. et al. Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State. Vaccines (Basel). 2022; 10(11): 1912. doi: 10.3390/vaccines10111912.
  3. Alfaro K, Maza M, Cremer M, Masch R, Soler M. Removing global barriers to cervical cancer prevention and moving towards elimination. Nat Rev Cancer. 2021; 21(10): 607-608. doi: 10.1038/s41568-021-00396-4.
  4. Bedard MC, de Alarcon A, Kou YF, Lee D, Sestito A, Duggins AL. et al. HPV Strain Predicts Severity of Juvenile-Onset Recurrent Respiratory Papillomatosis with Implications for Disease Screening. Cancers (Basel). 2021; 13(11): 2556. doi: 10.3390/cancers13112556.
  5. Bokan T, Ivanus U, Jerman T, Takac I, Arko D. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme. Radiol Oncol. 2021; 55(2): 187-195. doi: 10.2478/raon-2021-0001.
  6. Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D. et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Ukraine. Summary Report. 2023: 153. Available https://hpvcentre.net/statistics/reports/UKR.pdf.
  7. Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L. et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022; 51(9): 535-1541. doi: 10.1002/ijc.34002.
  8. Carlander AF, Jakobsen KK, Bendtsen SK, Garset-Zamani M, Lynggaard CD, Jensen JS. et al. A contemporary systematic review on repartition of HPV-positivity in oropharyngeal cancer worldwide. Viruses 2021, 13, 1326. doi: https://doi.org/10.3390/v13071326.
  9. Do EK, Rossi B, Miller CA, Ksinan AJ, Wheeler DC, Chukmaitov A. et al. Area-Level Variation and Human Papillomavirus Vaccination among Adolescents and Young Adults in the United States: A Systematic Review. Cancer Epidemiol Biomarkers Prev. 2021; 30(1): 13-21. doi: 10.1158/1055-9965.EPI-20-0617.
  10. Di Donato V, Caruso G, Petrillo M, Kontopantelis E, Palaia I, Perniola G. et al. Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis. Vaccines. 2021; 9: 410. doi: https://doi.org/10.3390/vaccines9050410.
  11. Ehman KM, Jenkins GD, Grimm JA, Cammack TL, Samuelson BJ, Stoll RJ. et al. Primary Human Papillomavirus Test Uptake and Cervical Cancer Screening Trends in the Midwest, United States. J Prim Care Community Health. 2024; 15: 21501319241251934. doi: 10.1177/21501319241251934.
  12. Galárraga G, López-Gil JF. Making human papillomavirus testing a public health priority in Ecuador. Front Public Health. 2025; 13: 1535580. doi: 10.3389/fpubh.2025.1535580.
  13. Gray P, Wang J, Nordqvist KS, Elfström KM, Dillner J. Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence. J Infect Dis. 2025; 231(4): 638-649. doi: 10.1093/infdis/jiaf032.
  14. Hernández-Silva CD, de Arellano AR, Pereira-Suárez AL, Ramírez-López IG. HPV and Cervical Cancer: Molecular and Immunological Aspects, Epidemiology and Effect of Vaccination in Latin American Women. Viruses. 2024; 16(3): 327. doi: 10.3390/v16030327.
  15. Hoes J, Pasmans H, Schurink-van 't Klooster TM, van der Klis FRM, Donken R, Berkhof J. et al. Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. Hum Vaccin Immunother. 2022; 18(1): 1908059. doi: 10.1080/21645515.2021.1908059.
  16. Karamousouli E, Sabale U, Valente S, Morosan F, Heuser M, Dodd O. et al. Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe – are we winning the RACE? Expert Rev Vaccines. 2025; 24(1): 11-26. doi: 10.1080/14760584.2024.2438759.
  17. Khairkhah N, Bolhassani A, Najafipour R. Current and future direction in treatment of HPV-related cervical disease. J Mol Med (Berl). 2022; 100(6): 829-845. doi: 10.1007/s00109-022-02199-y.
  18. Li Y, Wu X. Vaginal microbiome distinction in women with HPV+, cervical intraepithelial neoplasia, and cervical cancer, a retrospective study. Front Cell Infect Microbiol. 2025; 14: 1483544. doi: 10.3389/fcimb.2024.1483544.
  19. Liebermann E, Van Devanter N, Frías Gúzman N, Hammer MJ, Ompad D. Dominican Provider Attitudes Towards HPV Testing for Cervical Cancer Screening and, Current Challenges to Cervical Cancer Prevention in the Dominican Republic: a Mixed Methods Study. J Cancer Educ. 2021; 36(6): 1170-1185. doi: 10.1007/s13187-020-01746-w.
  20. Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management. Nat. Rev. Clin. Oncol. 2022, 19, 306–327. doi: https://doi.org/10.1038/s41571-022-00603-7.
  21. Lehtinen M, Gray P, Louvanto K, Vänskä S. In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers. Expert Rev. Vaccines 2022, 21, 735–738. doi: https://doi.org/10.1080/14760584.2022.2064279.
  22. Lin K, Hong Q, Fu Y, Tu H, Lin H, Huang J. et al. Cervical HPV infection and related diseases among 149,559 women in Fujian: an epidemiological study from 2018 to 2023. Front Microbiol. 2024; 15: 1418218. doi: 10.3389/fmicb.2024.1418218.
  23. Mariño JM, Rocha DAP, Reis RS, Souza MG, Soares SCC, Portugal JCA. et al. HPV-positive women living in isolated areas in Amazonas, Brazil: Clinical–epidemiological profile and cytological findings. Cad Saúde Colet. 2024; 32(1): 32010365. doi: 10.1590/1414-462X202432010365.
  24. Milano G, Guarducci G, Nante N, Montomoli E, Manini I. Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap? Vaccines (Basel). 2023; 11(6): 1060. doi: 10.3390/vaccines11061060.
  25. Del Mistro A, Frayle H, Menegaldo A, Favaretto N, Gori S, Nicolai P. et al. Age-independent increasing prevalence of Human Papillomavirus-driven oropharyngeal carcinomas in North-East Italy. Sci Rep. 2020; 10(1): 9320. doi: 10.1038/s41598-020-66323-z.
  26. Montoya-Fuentes H, Rodriguez-Martin A, Pena-Iniguez DI, Gonzalez-Bonilla CR, Rosales-Gomez RC, Gallegos-Arreola MP. et al. Molecular Detection and Typing of Human Papillomavirus in Men from Northwestern Mexico. Arch Med Res. 2020; 51(7): 675-682. doi: 10.1016/j.arcmed.2020.06.019.
  27. Mpunga T, Chantal Umulisa M, Tenet V, Rugwizangoga B, Milner DA Jr, Munyanshongore C. et al. Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status. Int J Cancer. 2020; 146(6): 1514-1522. doi: 10.1002/ijc.32491.
  28. Osmani V, Hörner L, Nkurunziza T, Rank S, Tanaka LF, Klug SJ. Global prevalence of cervical human papillomavirus in women aged 50 years and older with normal cytology: a systematic review and meta-analysis. Lancet Microbe. 2025; 6(1): 100955. doi: 10.1016/j.lanmic.2024.100955.
  29. Petca A, Borislavschi A, Zvanca ME, Petca RC, Sandru F, Dumitrascu MC. Non-sexual HPV transmission and role of vaccination for a better future (Review). Exp Ther Med. 2020; 20(6): 186. doi: 10.3892/etm.2020.9316.
  30. Pimple S, Mishra G. Cancer cervix: Epidemiology and disease burden. Cytojournal. 2022; 19: 21. doi: https://doi.org/10.25259/CMAS_03_02_2021.
  31. Quang C, Chung AW, Frazer IH, Toh ZQ, Licciardi PV. Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies? Trends Immunol. 2022; 43(10): 815-825. doi: 10.1016/j.it.2022.07.011.
  32. Racovitan V, Goodman E, Cheung WY, Nichols AC, Caulley L, Wurzba S. Human papillomavirus (HPV) related oropharyngeal cancers in Canada: A multicenter retrospective cohort study. Hum Vaccin Immunother. 2025; 21(1): 2486768. doi: 10.1080/21645515.2025.2486768.
  33. Ramírez-de-Arellano A, Villegas-Pineda JC, Hernández-Silva CD, Pereira-Suárez AL. The Relevant Participation of Prolactin in the Genesis and Progression of Gynecological Cancers. Front Endocrinol (Lausanne). 2021; 12: 747810. doi: 10.3389/fendo.2021.747810.
  34. Ruckriegl S, Loris J, Wert K, Bauerschmitz G, Gallwas J, Gründker C. Knockdown of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances Tumor-supportive Properties in Cervical Carcinoma Cells. Cancer Genomics Proteomics. 2023; 20(3): 281-297. doi: 10.21873/cgp.20381.
  35. Sackey ME, Markey K, Grealish A. Healthcare professional’s promotional strategies in improving Human papillomavirus (HPV) vaccination uptake in adolescents: A systematic review. Vaccine. 2022; 40(19): 2656-2666. doi: 10.1016/j.vaccine.2022.03.054.
  36. Sami J, Makajio SL, Jeannot E, Kenfack B, Viñals R, Vassilakos P. et al. Smartphone-Based Visual Inspection with Acetic Acid: An Innovative Tool to Improve Cervical Cancer Screening in Low-Resource Setting. Healthcare (Basel). 2022; 10(2): 391. doi: 10.3390/healthcare10020391.
  37. Santella B, Schettino MT, Franci G, De Franciscis P, Colacurci N, Schiattarella A. et al. Microbiota and HPV: The role of viral infection on vaginal microbiota. J. Med. Virol. 2022; 94: 4478–4484. doi: https://doi.org/10.1002/jmv.27837.
  38. Serrano B, Ibáñez R, Robles C, Peremiquel-Trillas P, de Sanjosé S, Bruni L. Worldwide use of HPV self-sampling for cervical cancer screening. Prev Med. 2022; 154: 106900. doi: 10.1016/j.ypmed.2021.106900.
  39. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B. et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023; 11(2): 197-206. doi: 10.1016/S2214-109X(22)00501-0.
  40. Shapiro GK. HPV Vaccination: An Underused Strategy for the Prevention of Cancer. Curr Oncol. 2022; 29(5): 3780-3792. doi: 10.3390/curroncol29050303.
  41. Thinley Dorji, Tshomo U, Gyamtsho S, Tamang ST, Wangmo S, Pongpirul K. Gender-neutral HPV elimination, cervical cancer screening, and treatment: Experience from Bhutan. Int J Gynaecol Obstet. 2022; 156(3): 425-429. doi: 10.1002/ijgo.13728.
  42. Tjalma WAA, van Heerden J, Van den Wyngaert T. If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment? Eur J Obstet Gynecol Reprod Biol. 2022; 269: 98-101. doi: 10.1016/j.ejogrb.2021.11.008.
  43. Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024; 404(10451): 435-444. doi: 10.1016/S0140-6736(24)01097-3.
  44. Wendland EM, Kops NL, Bessel M, Comerlato J, Maranhão AGK, Souza FMA. et al. Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women. Vaccine. 2021; 39(13): 1840-1845. doi: 10.1016/j.vaccine.2021.02.040.
  45. Yazdani Z, Rafiei A, Valadan R, Ashrafi H, Pasandi M, Kardan M. Designing a potent L1 protein-based HPV peptide vaccine: A bioinformatics approach. Comput Biol Chem. 2020; 85: 107209. doi: 10.1016/j.compbiolchem.2020.107209.
  46. Zhao X, Shen S, Su C, Chang J, Yan Y, Zhao J. Epidemiological study of HPV infection in 24,588 rural women in Luonan, China. Gynecol Oncol Rep. 2024; 57: 101669. doi: 10.1016/j.gore.2024.101669.
  47. Zhetpisbayeva I, Kassymbekova F, Sarmuldayeva S, Semenova Y, Glushkova N. Cervical Cancer Prevention in Rural Areas. Ann Glob Health. 2023; 89(1): 75. doi: 10.5334/aogh.4133.
Publication:
«World of Medicine and Biology» Vol. 21 No. 93 (2025) , с. 242-250
УДК 616-022.7:578.891.1(477)
DOI:
https://doi.org/10.26724/2079-8334-2025-3-93-242-250